Vapeitalia Partners with UK E-Liquid Brand Vampire Vape to Launch Exclusive Flavors and New Product Line in Italy

Aug.29.2025
Vapeitalia Partners with UK E-Liquid Brand Vampire Vape to Launch Exclusive Flavors and New Product Line in Italy
UK e-liquid brand Vampire Vape is entering the Italian market through an exclusive partnership with Vapeitalia. The collaboration will introduce the brand’s signature flavors Heisenberg and Pinkman, along with the new Purple Craze Ice. At the same time, Vampire Vape’s Bar Salts range will make its Italian debut, offering users a diverse selection of fruit flavors.

Key Points

  • Exclusive Partnership: Vapeitalia becomes Vampire Vape’s sole direct importer in Italy.
  • Signature Flavors: Heisenberg, Pinkman, and the new Purple Craze Ice debut in Italy.
  • New Highlight: Purple Craze Ice blends Heisenberg and Pinkman for a fruity, minty, icy profile.
  • Range Expansion: The Bar Salts series, featuring multiple fruit mixes, also launches.
  • Timing: Eight flavors to hit the Italian market in early September.

 


 

2Firsts, August 29, 2025 — Citing Sigmagazine, Italian vape retailer Vapeitalia—founded by Adriano, Gimmy, and Raffaele Esposito—has announced an exclusive partnership with UK e-liquid brand Vampire Vape, officially introducing the brand to the Italian market.

 

According to the agreement, Vapeitalia will be the sole direct importer in Italy for Vampire Vape’s flagship flavors, including Heisenberg, Pinkman, and the newly launched Purple Craze Ice.

 

Purple Craze Ice is drawing particular attention. Combining Vampire Vape’s two iconic flavors—Heisenberg and Pinkman—it delivers a berry-forward blend with mint and an icy finish, intended to “surprise from the very first puff.” Formats include 20/60 Shot, 10+10 Mini Shot, and 10ml concentrated aroma.

 

Vapeitalia will also bring Vampire Vape’s Bar Salts series to Italy. Known for its diverse fruit combinations, the series likewise comes in 20/60 Shot, 10+10 Mini Shot, and 10ml concentrated aroma options to suit varied consumer preferences.

 

Starting in early September 2025, eight flavors will be available in Italy:

  • Blue Sour Raspberry
  • Pineapple Ice
  • Blueberry Raspberry Strawberry
  • Peach Pineapple Watermelon
  • Cherry Raspberry Apple
  • Passionfruit Peach Lemon
  • Dragonfruit Raspberry Grape
  • Fizzy Orange

 

This partnership not only broadens flavor choices for Italian consumers but also marks another step in Vampire Vape’s ongoing expansion across Europe.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
The UK High Court has ordered Chinese vape manufacturer Shenzhen SKE Technology to provide £569,039 ($776,000) in security for costs in its design infringement proceedings against Vapepen London and other defendants over its Crystal Bar vape product. The court did not accept the defendants’ main argument that recovering costs from a China-based company would face significant enforcement obstacles, but found that SKE had not sufficiently disclosed its own financial position. The order is procedural and does not determine the underlying infringement claims.
News
Aug.21
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22